Our findings demonstrate that cell-autonomous STAT2 enhances colorectal tumor growth and correlates with poorer outcomes through mechanisms independent of IFN-I signaling, highlighting STAT2 signaling as a potential therapeutic target in CRC. This evidence concerns the gene STAT2 and colorectal carcinoma.